Methylation of <i>SLC45A4</i> and <i>AHSP</i> gene in peripheral blood leukocytes and the risks of breast cancer: a case-control study

FU Qingzhen; LI Dapeng; FU Jinming; LIU Yupeng; SUN Hongru; ZHANG Lei; ZHANG Xianyu; PANG Da; ZHAO Yashuang

doi:10.16462/j.cnki.zhjbkz.2024.01.009

Volume 28 Issue 1

Jan. 2024

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2024 > 28(1): 56-63

FU Qingzhen, LI Dapeng, FU Jinming, LIU Yupeng, SUN Hongru, ZHANG Lei, ZHANG Xianyu, PANG Da, ZHAO Yashuang. Methylation of SLC45A4 and AHSP gene in peripheral blood leukocytes and the risks of breast cancer: a case-control study[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(1): 56-63. doi: 10.16462/j.cnki.zhjbkz.2024.01.009

Citation:

FU Qingzhen, LI Dapeng, FU Jinming, LIU Yupeng, SUN Hongru, ZHANG Lei, ZHANG Xianyu, PANG Da, ZHAO Yashuang. Methylation of SLC45A4 and AHSP gene in peripheral blood leukocytes and the risks of breast cancer: a case-control study[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(1): 56-63. doi: 10.16462/j.cnki.zhjbkz.2024.01.009

Citation:

PDF( 1339 KB)

Methylation of SLC45A4 and AHSP gene in peripheral blood leukocytes and the risks of breast cancer: a case-control study

doi: 10.16462/j.cnki.zhjbkz.2024.01.009

1.
Department of Epidemiology, School of Public Health, Harbin Medical University, Harbin 150081, China
2.
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China

Funds:

National Natural Science Foundation of China 81172743

Heilongjiang Provincial Natural Science Foundation of China ZD2021H001

More Information

Corresponding author: ZHAO Yashuang, E-mail: zhao_yashuang@263.net
Received Date: 2023-03-22
Rev Recd Date: 2023-09-27

Available Online: 2024-02-05

Publish Date: 2024-01-10

Abstract

Abstract

Objective To investigate the relationship between peripheral blood leukocyte solute carrier family 45 member 4 (SLC45A4) and alpha hemoglobin stabilizing protein (AHSP) gene methylation and the risk of breast cancer. Methods Datasets GSE51032, GSE104942 and GSE89093 were used to identify genes that potentially associated with the risk of breast cancer through differential methylation analysis and other methods. A case-control study with 545 breast cancer patients and 524 cancer-free controls was carried out to validate the correlation between the methylation levels of the screened genes and breast cancer susceptibility. Results In this study, four genes were selected. After controlling for potential confounding factors, hypermethylation of SLC45A4 and AHSP was associated with lower breast cancer risk (OR_adj=0.218, 95% CI: 0.158-0.299; OR_adj=0.535, 95% CI: 0.384-0.741, respectively). The association of SLC45A4 hypermethylation with breast cancer remained statistically significant in different subgroups. The maximum value of OR_adj was 0.427(95% CI: 0.270-0.679) and the minimum value was 0.153 (95% CI: 0.085-0.274). However, the association of AHSP hypermethylation with breast cancer risk was statistically significant only in Luminal A, Luminal B subtypes, estrogen receptor + (ER+), and ≤60 age group. The association of heterogeneous nuclear ribonucleoproteins C (HNRNPC) methylation with the risk of breast cancer in our case-control study was inconsistent to the results of public datasets (OR_adj=0.747, 95% CI: 0.569-0.980). There was no statistically significant association between zinc finger protein 425 (ZNF425) methylation and breast cancer risk (P=0.158). Conclusions Hypermethylation of SLC45A4 and AHSP in peripheral blood leukocytes may serve as protective factors for breast cancer.
- Breast cancer,
- DNA methylation,
- Solute carrier family 45 member 4,
- α hemoglobin stabilizing protein

FullText(HTML)

References(12)

References

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	Karsli-Ceppioglu S, Dagdemir A, Judes G, et al. Epigenetic mechanisms of breast cancer: an update of the current knowledge[J]. Epigenomics, 2014, 6(6): 651-664. DOI: 10.2217/epi.14.59.
[3]	Laird PW. The power and the promise of DNA methylation markers[J]. Nat Rev Cancer, 2003, 3(4): 253-266. DOI: 10.1038/nrc1045.
[4]	Esteller M. Epigenetics in cancer[J]. N Engl J Med, 2008, 358(11): 1148-1159. DOI: 10.1056/nejmra072067.
[5]	Prajzendanc K, Domagała P, Hybiak J, et al. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer[J]. Int J Cancer, 2020, 146(5): 1293-1298. DOI: 10.1002/ijc.32655.
[6]	Xu ZL, Bolick SC, DeRoo LA, et al. Epigenome-wide association study of breast cancer using prospectively collected sister study samples[J]. J Natl Cancer Inst, 2013, 105(10): 694-700. DOI: 10.1093/jnci/djt045.
[7]	Ge AQ, Gao S, Liu YP, et al. Methylation of WT1, CA10 in peripheral blood leukocyte is associated with breast cancer risk: a case-control study[J]. BMC Cancer, 2020, 20(1): 713. DOI: 10.1186/s12885-020-07183-8.
[8]	Fu JM, Zhang L, Li DP, et al. DNA methylation of imprinted genes KCNQ1, KCNQ1OT1, and PHLDA2 in peripheral blood is associated with the risk of breast cancer[J]. Cancers, 2022, 14(11): 2652. DOI: 10.3390/cancers14112652.
[9]	Vitavska O, Wieczorek H. Putative role of an SLC45 H+/sugar cotransporter in mammalian spermatozoa[J]. Pflugers Arch, 2017, 469(11): 1433-1442. DOI: 10.1007/s00424-017-2024-9.
[10]	Chen WY, Huang FT, Huang J, et al. SLC45A4 promotes glycolysis and prevents AMPK/ULK1-induced autophagy in TP53 mutant pancreatic ductal adenocarcinoma[J]. J Gene Med, 2021, 23(9): e3364. DOI: 10.1002/jgm.3364.
[11]	Kihm AJ, Kong Y, Hong W, et al. An abundant erythroid protein that stabilizes free alpha-haemoglobin[J]. Nature, 2002, 417(6890): 758-763. DOI: 10.1038/nature00803.
[12]	Pinho FO, de Albuquerque DM, Olalla Saad ST, et al. Reduction of AHSP synthesis in hemin-induced K562 cells and EPO-induced CD34(+) cells leads to alpha-globin precipitation, impairment of normal hemoglobin production, and increased cell death[J]. Exp Hematol, 2008, 36(3): 265-272. DOI: 10.1016/j.exphem.2007.11.003.